RecruitingHematopoietic and Lymphatic System NeoplasmMalignant Solid NeoplasmMetastatic Malignant Solid Neoplasm

Collection and Storage of Tissue and Blood Samples From Patients With Cancer

Eligible age

0.2+ yrs

Accepts

All genders

Locations

23 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This study collects and stores tissue and blood samples from patients with cancer. Collecting and storing samples of tissue and blood from patients with cancer to study in the laboratory may help scientists create new and better models to learn about cancer and to test new cancer drugs.

Sponsor: National Cancer Institute LAO

You may qualify if…

✓ Patients older than 2 months of age who are being evaluated, treated, or enrolled in a clinical trial for cancer at participating sites
✓ Patients with a histologically or cytologically confirmed diagnosis of cancer
✓ Patients without histologically or cytologically confirmed diagnosis of cancer, but for whom approval has been requested and received from the coordinating site study coordinator
✓ Requests for coordinating site approval should only be made if the patient's existing work-up at the time of the request demonstrates a combination of two or more of the following indicating the greater likelihood of a cancerous process in the assessment of the treating physician:
✓ Radiographic imaging (computed tomography \[CT\], magnetic resonance imaging \[MRI\], etc.)
✓ Elevated tumor markers
✓ Clinical symptoms
✓ Documented risk factors, known genetic changes (mutation, deletion, fusion, etc.), and/or known familial cancer history or syndrome

You may not qualify if…

✕ Patients with cancer-like syndromes and/or blood disorders such as systemic mastocytosis, Langerhans cell histiocytosis, chronic eosinophilic leukemia/hypereosinophilic syndrome, lymphomatoid granulomatosis, or monoclonal gammopathy of undetermined significance (MGUS)
✕ Patients with invasive fungal infections
✕ Patients with active and/or uncontrolled bacterial, fungal, or viral infections or who are still recovering from an infection
✕ Actively febrile patients with uncertain etiology of febrile episode
✕ All antibiotics prescribed for the treatment of a bacterial infection should be completed at least 1 week (7 days) prior to collection
✕ Patients with a hematologic malignancy who are treated with an antibiotic, anti-fungal, and/or anti-viral medication for an active infection who then remain on the treatment for prophylaxis following resolution of the infection as assessed by the treating physician are not excluded
✕ No recurrence of fever or other symptoms related to infection for at least 1 week (7 days) following completion of antibiotics
✕ Patients receiving antibiotics, antifungals, and/or antivirals for prophylaxis are permissible